Autologous Stem Cell Transplantation for Follicular Lymphoma

Indications and Outcomes

The American Society of Hematology recommends ASCT specifically for young (<65-year-old) fit patients who relapse within 12 months from the end of frontline chemoimmunotherapy and achieve a response to chemoimmunotherapy reinduction 1, 2, 3
ASCT is considered a therapeutic option in young (<65-year-old) fit patients who relapse after at least 12 months from the end of frontline chemoimmunotherapy and achieve a response to chemoimmunotherapy reinduction 1, 2, 3
The American Society of Hematology considers ASCT typically not used as first-line therapy but as a salvage treatment for relapsed disease 4, 3

For patients who relapse after or are refractory to ASCT, allogeneic stem cell transplantation is recommended by the American Society of Hematology 1, 2, 3

The American Society of Hematology states there is insufficient evidence to support universal rituximab maintenance in patients achieving a response after ASCT 1, 2, 3